title: Doxorubicin coupled to lactosaminated albumin inhibits the growth of hepatocellular carcinomas induced in rats by diethylnitrosamine.
abstract: OBJECTIVE
  The hepatocyte receptor for asialoglycoproteins internalizes galactosyl terminating macromolecules which can be used as hepatotropic drug carriers. Since this receptor is also expressed on the cells of well differentiated human hepatocellular carcinomas (HCCs), we studied whether conjugation of doxorubicin (DOXO) with lactosaminated human albumin (L-HSA) increases the drug efficacy on HCCs induced in rats by diethylnitrosamine (DENA).
  
  
  METHODS
  DENA was given in the drinking water for 8 weeks. One week after the last day of DENA administration, animals were randomly assigned to three groups. Each group was administered with either saline, free or coupled DOXO (1 microg/g). Rats received 4 weekly intravenous injections. One week after the last administration, rats were killed and HCC development was evaluated by counting the tumor nodules on the surface of hepatic lobes.
  
  
  RESULTS
  In rats treated with L-HSA coupled DOXO the number of neoplastic nodules was significantly lower (P < 0.05) than that counted in animals injected with saline or with free DOXO. Coupled DOXO did not decrease body rat weight, which was markedly reduced by the free drug.
  
  
  CONCLUSIONS
  Conjugation with L-HSA increased the antineoplastic efficacy and decreased the systemic toxicity of DOXO administered to rats with HCCs produced by DENA.
authors: Department of Experimental Pathology, University of Bologna, via San Giacomo, 14 40126 Bologna, Italy. luigi.fiume@unibo.it
authors: Luigi
authors: L
authors: Fiume
authors: Luigi
authors: L
authors: Bolondi
authors: Corrado
authors: C
authors: Busi
authors: Pasquale
authors: P
authors: Chieco
authors: Felix
authors: F
authors: Kratz
authors: Marcella
authors: M
authors: Lanza
authors: Alessandro
authors: A
authors: Mattioli
authors: Giuseppina
authors: G
authors: Di Stefano
mesh_terms: D000818:Animals; D001835:Body Weight / Q000187:drug effects; D006528:Carcinoma, Hepatocellular / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology; D004052:Diethylnitrosamine; D004195:Disease Models, Animal; D004317:Doxorubicin / Q000493:pharmacokinetics* / Q000627:therapeutic use*; D008113:Liver Neoplasms / Q000139:chemically induced / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008657:Metabolic Clearance Rate; D051381:Rats; D017208:Rats, Wistar; D012709:Serum Albumin / Q000627:therapeutic use*; D014018:Tissue Distribution
chemical_list: D012709:Serum Albumin; C046912:lactosaminated serum albumin; D004052:Diethylnitrosamine; D004317:Doxorubicin